Skip to main content

Table 3 Biochemical markers in the two groups before and after PCI

From: Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience

 

Eptifibatide + ticagrelor (baseline)

Ticagrelor (baseline)

Eptifibatide + ticagrelor

(post-PCI)

Ticagrelor (post-PCI)

hs-TnT

51.40 ± 27.51

53.23 ± 26.13

123.04 ± 67.85*

194.82 ± 99.94

NT-proBNP

395.81 ± 202.09

391.58 ± 224.62

1166.07 ± 646.51*

1330.97 ± 695.16

hs-CRP

44.98 ± 21.44

43.83 ± 18.59

161.35 ± 90.20

171.48 ± 63.39

h-FABP

2799.79 ± 1223.05

2571.65 ± 1133.39

4226.13 ± 1824.56*

4755.89 ± 1694.19

  1. *P < 0.01 vs. ticagrelor group post-PCI
  2. h-FABP: heart-type fatty acid-binding protein; hs-CRP: high-sensitivity C-reactive protein; hs-TnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-brain natriuretic peptide; PCI: percutaneous coronary intervention
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us